Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix ML, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina JM, Robert J, Tod M, Fagard C, Chêne G; ANRS 129 BKVIR Trial Group.

J Antimicrob Chemother. 2016 Mar;71(3):783-93. doi: 10.1093/jac/dkv384. Epub 2015 Dec 17.

PMID:
26679250
2.

Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.

Ghislain M, Bastard JP, Meyer L, Capeau J, Fellahi S, Gérard L, May T, Simon A, Vigouroux C, Goujard C; ANRS-COPANA Cohort Study Group.

PLoS One. 2015 Dec 4;10(12):e0144317. doi: 10.1371/journal.pone.0144317. eCollection 2015.

3.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

4.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

5.

Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study.

Legeai C, Vigouroux C, Souberbielle JC, Bouchaud O, Boufassa F, Bastard JP, Carlier R, Capeau J, Goujard C, Meyer L, Viard JP; ANRS-COPANA Cohort Study Group.

PLoS One. 2013 Sep 18;8(9):e74868. doi: 10.1371/journal.pone.0074868. eCollection 2013.

6.

Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.

Boufassa F, Goujard C, Viard JP, Carlier R, Lefebvre B, Yeni P, Bouchaud O, Capeau J, Meyer L, Vigouroux C; ANRS COPANA Cohort Study Group.

Antivir Ther. 2012;17(1):91-100. doi: 10.3851/IMP1916.

7.

Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.

Gasnault J, Costagliola D, Hendel-Chavez H, Dulioust A, Pakianather S, Mazet AA, de Goer de Herve MG, Lancar R, Lascaux AS, Porte L, Delfraissy JF, Taoufik Y; ANRS 125 Trial Team.

PLoS One. 2011;6(6):e20967. doi: 10.1371/journal.pone.0020967. Epub 2011 Jun 30.

8.

Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT).

Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S; INSIGHT-ESPRIT Study Group.

HIV Med. 2011 Apr;12(4):219-27. doi: 10.1111/j.1468-1293.2010.00875.x. Epub 2010 Aug 31.

9.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration, Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

10.

Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.

Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, Rosenthal E, Jougla E, Cacoub P, Salmon D, Chêne G, Morlat P; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group.

Clin Infect Dis. 2009 Mar 1;48(5):633-9.

PMID:
19202627
11.

Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.

Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, Pol S, Carrat F, Cacoub P; French National Agency for Research on AIDS; Viral Hepatitis-HC02-Ribavic Study Team.

Clin Infect Dis. 2008 Mar 1;46(5):768-74. doi: 10.1086/527565.

PMID:
18248298
12.

Cutaneous malignant fibrous histiocytoma in an HIV-positive patient.

Blatière V, De Boever CM, Jacot W, Durand L, Guillot B.

J Eur Acad Dermatol Venereol. 2007 Jan;21(1):106-7. No abstract available.

PMID:
17207179
13.

Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?

Badiou S, De Boever CM, Terrier N, Baillat V, Cristol JP, Reynes J.

J Infect. 2006 May;52(5):335-8. Epub 2005 Sep 19.

PMID:
16176835
14.

CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains.

Lin YL, Portales P, Segondy M, Baillat V, de Boever CM, Le Moing V, Réant B, Montes B, Clot J, Reynes J, Corbeau P.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):530-6.

PMID:
16044003
15.

T-Cell surface CCR5 density is not correlated with hepatitis severity in hepatitis C virus/HIV-coinfected individuals: implications for the therapeutic use of CCR5 antagonists.

Vincent T, Portales P, Baillat V, de Boever CM, Le Moing V, Vidal M, Ducos J, Clot J, Reynes J, Corbeau P.

J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):305-9.

PMID:
15735449
16.

Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.

Molina JM, Marcelin AG, Pavie J, Heripret L, De Boever CM, Troccaz M, Leleu G, Calvez V; AI454-176 JAGUAR Study Team.

J Infect Dis. 2005 Mar 15;191(6):840-7. Epub 2005 Feb 10.

PMID:
15717257
17.

Vitamin E supplementation increases the expression of the CCR5 coreceptor in HIV-1 infected subjects.

Portales P, Guerrier T, Clot J, Corbeau P, Mettling C, Lin YL, Baillat V, de Boever CM, Le Moing V, Tramoni C, Reynes J, Segondy M.

Clin Nutr. 2004 Oct;23(5):1244-5. No abstract available.

PMID:
15380918
18.

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.

Peyrière H, Reynes J, Rouanet I, Daniel N, de Boever CM, Mauboussin JM, Leray H, Moachon L, Vincent D, Salmon-Céron D.

J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):269-73.

PMID:
15076241
19.

Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.

Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group.

J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9.

PMID:
14657760
20.

Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.

Badiou S, De Boever CM, Dupuy AM, Baillat V, Cristol JP, Reynes J.

AIDS. 2003 Mar 28;17(5):772-4. No abstract available.

PMID:
12646808

Supplemental Content

Loading ...
Support Center